Ipamorelin (5 mg x 10) is a synthetic growth hormone–releasing peptide (GHRP) studied for its ability to stimulate the natural secretion of growth hormone (GH). It selectively binds to the ghrelin (GHS-R1a) receptor in the pituitary gland, encouraging endogenous GH release without significantly elevating other hormones such as cortisol or prolactin in most research observations. This selective mechanism has made Ipamorelin a focus in experimental settings examining muscle protein synthesis, recovery dynamics, sleep regulation, and metabolic function. The 5 mg x 10 presentation typically indicates multiple research vials designed for structured laboratory protocols and controlled investigative use.
CJC-1295 no DAC (5 mg x 10) is a modified analog of growth hormone–releasing hormone (GHRH) that promotes pulsatile GH secretion by stimulating the GHRH receptor pathway. The “no DAC” designation refers to the absence of the Drug Affinity Complex, resulting in a shorter half-life and allowing for more precise timing in experimental administration. When discussed together, Ipamorelin and CJC-1295 no DAC are often described in research literature as complementary compounds, as they activate distinct receptors to support endogenous GH release. This combination has been explored in laboratory models focused on anabolic signaling, body composition research, and recovery physiology, while remaining primarily within investigative and non-therapeutic contexts.
Reviews
There are no reviews yet.